Molbio Diagnostics Ltd.
NSE & BSE₹768–807
₹ 658 Cr
18 Shares
₹ 13,824
₹1
Financial Summary
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| 14,456.87 | 10,204.18 | |
| 94.83 | 75.18 | |
| 14,551.7 | 10,279.36 | |
| 11,242.44 | 7,581.95 | |
| 2,311.37 | 1,944.28 | |
| 1,641.4 | 1,385.79 |
Subscription Details
Subscription
IPO Timeline
IPO Offer Start
10 Aug 2026
IPO Offer Ends
12 Aug 2026
17 Aug 2026
Use of Proceeds
| # | Purpose | Amount (₹ Million) |
|---|---|---|
| 1 | Funding capital expenditure towards the setting up of infrastructure for our research and | 1,251.21 |
| 2 | Funding capital expenditure towards the purchase of certain plant, machinery and other | 808.05 |
Promoters
Book Running Lead Managers
Promoter Shareholding
Pre-IPO
44.89%
Promoter stake
Post-IPO
41.29%
Promoter stake
Offered to Public
81,58,529
shares
Post Share Capital
4,75,82,801
shares
IPO Registrar
KFIN Technologies Ltd.
About the Company
We are an innovative point-of-care (“POC”) diagnostics company focused on expanding access to accurate, rapidand cost-effective healthcare technologies to diagnose infectious and non-communicable diseases. We havedeveloped our ‘Truenat’ platform, which is a novel POC polymerase chain reaction (“PCR”) platform that canoperate in resource limited settings since its battery operated, facilitating decentralized diagnosis within an hour.As of March 31, 2025, Truenat is patented in more than 100 countries for the diagnosis of multiple infectious andnon-communicable diseases. As of March 31, 2025, we offer molecular testing for 30 diseases, includingtuberculosis (“TB”), COVID, Hepatitis B and C, Human immunodeficiency virus (“HIV”), and HumanPapillomavirus (“HPV”) with 42 assays. We operate in an oligopolistic market with high entry barriers, evidencedby the fact that our platform underwent 13 years of R&D to obtain Indian Council of Medical Research (“ICMR”)certification and our ‘Truenat’ test chip for diagnosing TB is the only one by an Indian company and one of theonly two rapid molecular tests in the world, which has been endorsed by the World Health Organization (“WHO”)for initial diagnosis of TB and rifampicin resistance detection using molecular diagnostic technology. (Source:1Lattice Report). We also provide devices, enabling radiology, digital pathology and breast health screening,through our Subsidiary, Prognosys, Associate, OptraScan and collaboration partner - UE Lifesciences. Further, weare focussed towards building a pipeline of additional products and platforms that are currently at various stagesof development.
Use of Proceeds
1. Funding capital expenditure towards the setting up of infrastructure for a research and development facility and Center of Excellence which will be operated by our wholly-owned Subsidiary, Bigtec and connected office space for our Company, Subsidiaries and Associate,2. Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and3. General corporate purposes
Molbio Diagnostics Ltd. Latest News
News
Molbio Diagnostics informs about disclosure
Molbio Diagnostics informs about disclosure
Molbio Diagnostics informs about SAST
Molbio Diagnostics informs about press release
Molbio Diagnostics lists with 21% premium on the BSE
The scrip is currently trading at Rs. 1018.00, up by 211.00 points or 26.15% from its issue price
Molbio Diagnostics coming with IPO to raise up to Rs 950.03 crore
The issue will open for subscription on August 10, 2026 and will close on August 12, 2026
IPO FAQs
The Molbio Diagnostics Ltd. IPO has a total of ₹658 crore, calculated at the upper end of the .
The Molbio Diagnostics Ltd. IPO is priced at ₹768–807 per share. bids must fall within this , against a of ₹1 per share.
The for the Molbio Diagnostics Ltd. IPO is 18 shares, which is also the minimum order quantity — you have to apply for at least 18 shares, and in multiples of 18 beyond that.
The minimum investment in the Molbio Diagnostics Ltd. IPO is about ₹13,824 — one lot of 18 shares, calculated at the lower end of the .
Bidding at the cut-off or upper price raises the amount blocked in your account.
The Molbio Diagnostics Ltd. opens on 10 Aug 2026 and closes on 12 Aug 2026.
Applications have to be in before 5:00 PM IST on the closing day, and your UPI mandate needs to be approved by then as well.
Molbio Diagnostics Ltd. shares were listed on 17 Aug 2026 on BSE and NSE.
KFIN Technologies Ltd. is the for the Molbio Diagnostics Ltd. IPO.
The registrar processes the , refunds and the credit of shares to your demat account, so allotment-status queries go to them.
Molbio Diagnostics Ltd. IPO shares are listed on BSE and NSE.
Each Molbio Diagnostics Ltd. share has a of ₹1.
Face value is the nominal value recorded in the company's books and is separate from the issue price you pay.
held 44.89% of Molbio Diagnostics Ltd. before the IPO, which falls to 41.29% after the issue.
81,58,529 shares of Molbio Diagnostics Ltd. are being offered to the public in this issue.
The Molbio Diagnostics Ltd. IPO has been subscribed 70.26x overall — 186.39x, 49.80x, 12.96x and employees 13.28x.
figures update through the issue period until it closes.
- 1.Funding capital expenditure towards the setting up of infrastructure for a research and development facility and Center of Excellence which will be operated by our wholly-owned Subsidiary, Bigtec and connected office space for our Company, Subsidiaries and Associate
- 2.Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit
- 3.General corporate purposes
Kotak Mahindra Capital Co Ltd, IIFL Capital Services Ltd., Jefferies India Pvt Ltd. and Motilal Oswal Investment Advisors Pvt Ltd are the for the Molbio Diagnostics Ltd. IPO.
Pre-apply means placing your Molbio Diagnostics Ltd. application before the subscription window actually opens. The bid is held and forwarded to the exchange on the opening day, so you don't have to submit it in the rush of the first morning.
Applying early doesn't improve your chances — when an issue is oversubscribed, the for investors is decided by a lottery, not by who applied first. Your money is only blocked once the application reaches the exchange.
You can apply in the Molbio Diagnostics Ltd. IPO online using either UPI or ASBA as the payment method. ASBA applications are made through the net banking of a bank account that supports IPO applications — the bank blocks the amount in your account instead of debiting it. UPI applications are offered by brokers that don't provide banking services: you enter your UPI ID and then approve the mandate request in your UPI app.
Either route needs a demat account. You bid for at least one lot, at a price within the or at the cut-off price, and the money stays blocked in your bank account until the is finalised.
Your broker or bank confirms the bid once it has been submitted to the exchange, usually within a few minutes during the bidding window. A UPI application only goes live after you approve the mandate request — ignore it and the bid lapses, even though it looks placed.
You can check the Molbio Diagnostics Ltd. bid independently on the NSE or BSE IPO bid-verification page a day after applying. An ASBA application also shows up as a blocked amount in your bank statement.